Given the results proposed for the potential use of TGF-β in IVD degeneration [22,79,80,81,82,83,84], along with the dual nature of TGF-β’s role in the disease [31,86,87], it appears that administering TGF-β within the IVD is justified in the early and late stages of degenerative disc disease (Pfirrmann grades 2 and 5). This evidence concerns the gene TGFB1 and intervertebral disk degenerative disorder.